This study assessed the effects of thyroid hormones on the enzymes involved in l-arginine metabolism and the metabolites generated by the different metabolic pathways. Compounds of l-arginine metabolism were measured in the kidney, heart, aorta, and liver of euthyroid, hyperthyroid, and hypothyroid rats after 6 weeks of treatment. Enzymes studied were NOS isoforms (neuronal [nNOS], inducible [iNOS], and endothelial [eNOS]), arginases I and II, ornithine decarboxylase (ODC), ornithine aminotransferase (OAT), and l-arginine decarboxylase (ADC). Metabolites studied were l-arginine, l-citrulline, spermidine, spermine, and l-proline. Kidney heart and aorta levels of eNOS and iNOS were augmented and reduced (P < 0.05, for each tissue and enzyme) in hyper- and hypothyroid rats, respectively. Arginase I abundance in aorta, heart, and kidney was increased (P < 0.05, for each tissue) in hyperthyroid rats and was decreased in kidney and aorta of hypothyroid rats (P < 0.05, for each tissue). Arginase II was augmented in aorta and kidney (P < 0.05, for each tissue) of hyperthyroid rats and remained unchanged in all organs of hypothyroid rats. The substrate for these enzymes, l-arginine, was reduced (P < 0.05, for all tissues) in hyperthyroid rats. Levels of ODC and spermidine, its product, were increased and decreased (P < 0.05) in hyper- and hypothyroid rats, respectively, in all organs studied. OAT and proline levels were positively modulated by thyroid hormones in liver but not in the other tissues. ADC protein levels were positively modulated by thyroid hormones in all tissues. According to these findings, thyroid hormone treatment positively modulates different l-arginine metabolic pathways. The changes recorded in the abundance of eNOS, arginases I and II, and ADC protein in renal and cardiovascular tissues may play a role in the hemodynamic and renal manifestations observed in thyroid disorders. Furthermore, the changes in ODC and spermidine might contribute to the changes in cardiac and renal mass observed in thyroid disorders.
RaijLBayliC. Glomerular actions of nitric oxide. Kidney Int1995; 48: 20–32.
4.
JenkinsonCPGrodyWWCederbaumSD. Comparative properties of arginases. Comp Biochem Physiol B Biochem Mol Biol1996; 114: 107–32.
5.
MorrisSMJrBhamidipatiDKepka-LenhartD. Human type II arginase: sequence analysis and tissue-specific expression. Gene1997; 193: 157–61.
6.
ShiOKepka-LenhartDMorrisSMJrO’BrienWE. Structure of the murine arginase II gene. Mamm Genome1998; 9: 822–4.
7.
BugaGMSinghRPervinSRogersNESchmitzDAJenkinsonCPCederbaumSDIgnarroLJ. Arginase activity in endothelial cells: inhibition by N[omega]-hydroxy-l-arginine during high-output NO production. Am J Physiol1996; 271: H1988–98.
8.
IgnarroLJBugaGWieLHBauerPMWuGdel SoldatoP. Role of arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci USA2001; 98: 4202–42089.
ShihVE. Regulation of ornithine metabolism. Enzyme1981; 26: 254–8.
11.
ReyesAAKarlIEKlahrS. Role of arginine in health and in renal disease. Am J Physiol1994; 267: F331–46.
12.
BerryCLHenrichsKJ. Morphometric investigation of hypertrophy in the arteries of DOCA-hypertensive rats. J Physiol1982; 136: 85–94.
13.
MorrisseyJMcCrackenRIshidoyaSKlahrS. Partial cloning and characterization of an arginine decarboxylase in the kidney. Kidney Int1995; 47: 1458–61.
14.
Rodríguez-GómezISainzJWangensteenRMorenoJMDuarteJOsunaAVargasF. Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension2003; 42: 220–5.
15.
QuesadaASainzJWangensteenRRodriguez-GomezIVargasFOsunaA. Nitric oxide synthase activity in hyperthyroid and hypothyroid rats. Eur J Endocrinol2002; 147: 117–22.
16.
Rodríguez-GómezIWangensteenRMorenoJMChamorroVOsunaAVargasF. Effects of chronic inhibition of inducible nitric oxide synthase in hyperthyroid rats. Am J Physiol Endocrinol Metab2005; 288: E1252–7.
17.
VargasFBazMJLunaJDAndradeJJodarEHaroJM. Urinary excretion of digoxin-like immunoreactive factor and arginine vasopressin in hyper-and hypothyroid rats. Clin Sci1991; 81: 471–6.
18.
VargasFAtuchaNSabioJMQuesadaTGarcía-EstañJ. Pressure–diuresis–natriuresis response in hyper- and hypothyroid rats. Clin Sci1994; 87: 323–8.
19.
DhanakotiSNBrosnanJTHerzbergGRBrosnanME. Renal arginine synthesis: studies in vitro and in vivo. Am J Physiol1990; 259: E437–42.
20.
VargasFMorenoJMRodríguez-GómezIWangensteenRAlvarez-GuerraMOsunaAGarcía-EstañJ. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol2006; 154: 1–17.
21.
Rodríguez-GómezIBanegasIWangensteenRQuesadaAJimenezRGómez-MoralesMO’ValleFDuarteJVargasF. Influence of thyroid state on cardiac and renal capillary density and glomerular morphology in rats. J Endocrinol2012; 216: 1–10.
22.
VargasFFernández-RivasAGarcía EstañJGarcía del RíoC. Endothelium-dependent and endothelium-independent vasodilation in hyperthyroid and hypothyroid rats. Pharmacology1995; 51: 308–14.
23.
ChakrabartiNRayAK. Rise of intrasynaptosomal Ca2+ level and activation of nitric oxide synthase in adult rat cerebral cortex pretreated with 3-5-30-L-triiodothyronine. Neuropsychopharmacology2000; 22: 36–41.
24.
VaziriNDZhenminNOveisiF. Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension1998; 31: 1248–54.
25.
VargasFRodriguez-GómezIVargas-TenderoPJiménezEMontielM. The renin–angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. J Endocrinol2012; 213: 25–36.
26.
SinghGThompsonEBGulatiA. Altered endothelin 1 concentration in brain and peripheral regions during thyroid dysfunction. Pharmacology1994; 49: 184–91.
27.
PopoloAAdessoSPintoAAutoreGMarzoccoS. l-Arginine and its metabolites in kidney and cardiovascular disease. Amino Acids2014; 46: 2271–86.
28.
Rodríguez-Gómez I, Moreno JM, Jimenez R, Quesada A, Montoro-Molina S, Vargas-Tendero P, Wangensteen R, Vargas F. Effects of arginase inhibition in hypertensive hyperthyroid rats. Am J Hypertens (doi:10.1093/ajh/hpv049).
29.
PeggAEHibasamiH. Polyamine metabolism during cardiac hypertrophy. Am J Physiol1980; 239: E372–8.
30.
LinYZhangXWangLZhaoYLiHXiaoWXuCLiuJ. Polyamine depletion attenuates isoproterenol-induced hypertrophy and endoplasmic reticulum stress in cardiomyocytes. Cell Physiol Biochem2014; 34: 1455–65.
31.
CubriaJCRegueraRBalana-FouceROrdoñezCOrdoñezD. Polyamine-mediated heart hypertrophy induced by clenbuterol in the mouse. J Pharm Pharmacol1998; 50: 91–6.
32.
KucharzewskaPWelchJESvenssonKJBeltingM. Ornithine decarboxylase and extracellular polyamines regulate microvascular sprouting and actin cytoskeleton dynamics in endothelial cells. Exp Cell Res2010; 316: 2683–91.
33.
RaghavanSAVDikshitM. Vascular regulation by the l-arginine metabolites, nitric oxide and agmatine. Pharmacol Res2004; 49: 397–414.
34.
HayakawaHHirataYSuzukiEKimuraKKikuchiKNaganoTHirobeMOmataM. Long-term administration of l-arginine improves nitric oxide release from kidney in deoxycorticosterone acetate-salt hypertensive rats. Hypertension1994; 23: 752–6.
35.
AbreuGRFuturo-NetoHACabralAMVasquezEC. L-arginine restores the effect of ouabain on baroreceptor activity and prevents hypertension. Hypertension1999; 34: 729–32.
